• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EMAs board nominates Rasi as executive director

EMAs board nominates Rasi as executive director

October 5, 2015
CenterWatch Staff

The EMA’s management board has nominated professor Guido Rasi as the executive director of the agency. Rasi was selected from a shortlist of candidates provided by the European Commission.

Since November 2014, Rasi has served as principal adviser in charge of strategy following the judgment of the E.U. Civil Service Tribunal that annulled in part the 2011 selection procedure for the position of executive director of the EMA. From November 2011 to November 2014, he was the executive director of the EMA and a member of its management board.

Rasi was director-general of the Italian Medicines Agency from 2008 to 2011 and a member of the management board from 2004 and 2008. He was made full professor of microbiology at the University of Rome “Tor Vergata” in 2008.

From 2005 to 2008, he was director of the Institute of Molecular Medicine of the National Research Council in Rome. Rasi also worked at the Institute for Experimental Medicine of the National Research Council, Italy, and has previous teaching and research experience at the University of California, Berkeley.

Deputy Executive Director Andreas Pott will continue to lead EMA operations and to legally represent the agency until the new executive director has officially taken up his duties.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing